08/10/2022 | Press release | Distributed by Public on 08/10/2022 15:21
| | |
Per share
and accompanying common warrant |
| |
Per pre-funded warrant
and accompanying common warrant |
| |
Total
|
| |||||||||
Combined public offering price
|
| | | $ | 0.43 | | | | | $ | 0.429 | | | | | $ | 10,000,000 | | |
Underwriting discounts and commissions(1)
|
| | | $ | 0.028 | | | | | $ | 0.028 | | | | | $ | 652,086 | | |
Proceeds, before expenses, to us
|
| | | $ | 0.402 | | | | | $ | 0.401 | | | | | $ | 9,347,913 | | |
| | |
Page
|
| |||
ABOUT THIS PROSPECTUS SUPPLEMENT
|
| | | | S-1 | | |
FORWARD-LOOKING STATEMENTS
|
| | | | S-2 | | |
SUMMARY
|
| | | | S-3 | | |
THE OFFERING
|
| | | | S-10 | | |
RISK FACTORS
|
| | | | S-12 | | |
USE OF PROCEEDS
|
| | | | S-14 | | |
DILUTION
|
| | | | S-15 | | |
DESCRIPTION OF SECURITIES WE ARE OFFERING
|
| | | | S-16 | | |
UNDERWRITING
|
| | | | S-20 | | |
LEGAL MATTERS
|
| | | | S-24 | | |
EXPERTS
|
| | | | S-24 | | |
WHERE YOU CAN FIND ADDITIONAL INFORMATION
|
| | | | S-24 | | |
INCORPORATION BY REFERENCE
|
| | | | S-24 | | |
| | |
Page
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 2 | | |
INCORPORATION BY REFERENCE
|
| | | | 3 | | |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | 4 | | |
THE COMPANY
|
| | | | 5 | | |
RISK FACTORS
|
| | | | 9 | | |
USE OF PROCEEDS
|
| | | | 10 | | |
DESCRIPTION OF DEBT SECURITIES
|
| | | | 11 | | |
DESCRIPTION OF CAPITAL STOCK
|
| | | | 18 | | |
DESCRIPTION OF OTHER SECURITIES
|
| | | | 20 | | |
PLAN OF DISTRIBUTION
|
| | | | 22 | | |
LEGAL MATTERS
|
| | | | 25 | | |
EXPERTS
|
| | | | 25 | | |
Branded Product
|
| |
Approved Indication
|
| |
FDA Approval Date
|
| |
Commercial Launch Date
|
|
Adzenys XR-ODT (amphetamine) | | | Treatment of ADHD in patients 6 years and older | | | January 2016 | | | May 2016 | |
Cotempla XR-ODT (methylphenidate) | | | Treatment of ADHD in patients 6 to 17 years old | | | June 2017 | | | September 2017 | |
|
Public offering price per share of common stock (or pre-funded warrants in lieu thereof) and accompanying Warrant
|
| | | | | $ | 0.43 | | | ||||
|
Net tangible book value per share as of March 31, 2022
|
| | | $ | (0.66) | | | | | | | | |
|
Increase per share attributable to this offering
|
| | | $ | 0.43 | | | | | | | | |
|
As-adjusted net tangible book value per share after giving effect to this offering
|
| | | | | | | | | $ | (0.23) | | |
|
Dilution per share to new investors(1)(2)
|
| | | | | | | | | $ | (0.66) | | |
Name
|
| |
Number of
shares |
| |
Number of
pre-funded warrants |
| |
Number of
Warrants |
| |||||||||
Cantor Fitzgerald & Co.
|
| | | | 13,978,780 | | | | | | 1,137,500 | | | | | | 15,116,280 | | |
Cannaccord Genuity LLC
|
| | | | 7,527,034 | | | | | | 612,500 | | | | | | 8,139,534 | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | ||
Total
|
| | | | 21,505,814 | | | | | | 1,750,000 | | | | | | 23,255,814 | | |
| | | | | | | | | | | | |||||||||
| | |
Per share
and accompanying common warrant |
| |
Per pre-funded warrant
and accompanying common warrant |
| |
Total
|
| | | | |||||||
Combined public offering price
|
| | | $ | 0.43 | | | | | $ | 0.429 | | | | | $ | 10,000,000 | | | |
Underwriting discounts and commissions
|
| | | $ | 0.028 | | | | | $ | 0.028 | | | | | $ | 652,086 | | | |
Proceeds, before expenses, to us
|
| | | $ | 0.402 | | | | | $ | 0.401 | | | | | $ | 9,347,913 | | | |
| | |
Page
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 2 | | |
INCORPORATION BY REFERENCE
|
| | | | 3 | | |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | 4 | | |
THE COMPANY
|
| | | | 5 | | |
RISK FACTORS
|
| | | | 9 | | |
USE OF PROCEEDS
|
| | | | 10 | | |
DESCRIPTION OF DEBT SECURITIES
|
| | | | 11 | | |
DESCRIPTION OF CAPITAL STOCK
|
| | | | 18 | | |
DESCRIPTION OF OTHER SECURITIES
|
| | | | 20 | | |
PLAN OF DISTRIBUTION
|
| | | | 22 | | |
LEGAL MATTERS
|
| | | | 25 | | |
EXPERTS
|
| | | | 25 | | |
Branded Product
|
| |
Approved Indication
|
| |
FDA Approval Date
|
| |
Commercial Launch Date
|
|
Adzenys XR-ODT (amphetamine) | | | Treatment of ADHD in patients 6 years and older | | | January 2016 | | | May 2016 | |
Cotempla XR-ODT (methylphenidate) | | | Treatment of ADHD in patients 6 to 17 years old | | | June 2017 | | | September 2017 | |
Adzenys ER (amphetamine) oral suspension | | | Treatment of ADHD in patients 6 years and older | | | September 2017 | | | February 2018 | |